癌症免疫治疗新靶标VISTA及抗体研究进展

2020-02-20 Allan MedSci原创

Hummingbird Bioscience是一家创新性生物制药公司,致力于开发新型抗体疗法,其研究性新药HMBD-002是针对实体瘤的抗VISTA抗体。

近年来的肿瘤学研究发现,VISTAV-domain Ig suppressor of T-cell activationT细胞活化V结构域Ig抑制剂)是调节免疫力的分子之一。VISTA可使免疫系统的T细胞区室保持静止状态,并阻止免疫系统激活自身抗原。像其他的负免疫检查点调节剂一样,阻断癌症中的VISTA可能会增强宿主产生肿瘤特异性的保护性免疫反应。因此,VISTA可能是癌症免疫治疗新靶标,因为它可以强烈抑制机体抗肿瘤免疫反应的激活,更为重要的是,VISTA细胞的存在通常与癌症免疫疗法的耐药有关。

Hummingbird Bioscience是一家创新性生物制药公司,致力于开发新型抗体疗法,其研究性新药HMBD-002是针对实体瘤的抗VISTA抗体。HMBD-002能够阻止了VISTA的激活,关闭使免疫细胞处于休眠状态的信号。临床前研究表明,HMBD-002可以强烈抑制肿瘤的生长,无论是单一疗法,还是与抗PDL1疗法联合使用,都可以更有效地抑制肿瘤的生长。


原始出处:

https://www.firstwordpharma.com/node/1702341?tsid=4

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1669230, encodeId=5f4a16692309f, content=<a href='/topic/show?id=561b1846324' target=_blank style='color:#2F92EE;'>#VISTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18463, encryptionId=561b1846324, topicName=VISTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d26532205, createdName=muzishouyi, createdTime=Sat Nov 21 17:07:00 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352853, encodeId=133513528537a, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 22 14:07:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381246, encodeId=e18313812465d, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Feb 22 14:07:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
    2020-11-21 muzishouyi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1669230, encodeId=5f4a16692309f, content=<a href='/topic/show?id=561b1846324' target=_blank style='color:#2F92EE;'>#VISTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18463, encryptionId=561b1846324, topicName=VISTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d26532205, createdName=muzishouyi, createdTime=Sat Nov 21 17:07:00 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352853, encodeId=133513528537a, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 22 14:07:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381246, encodeId=e18313812465d, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Feb 22 14:07:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
    2020-02-22 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1669230, encodeId=5f4a16692309f, content=<a href='/topic/show?id=561b1846324' target=_blank style='color:#2F92EE;'>#VISTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18463, encryptionId=561b1846324, topicName=VISTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d26532205, createdName=muzishouyi, createdTime=Sat Nov 21 17:07:00 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352853, encodeId=133513528537a, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 22 14:07:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381246, encodeId=e18313812465d, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Feb 22 14:07:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]